Evidence map›Paper›PMID 38041717›Full record

Observational studyEuropean radiology2024

CT versus MR guidance for radiofrequency ablation in patients with colorectal liver metastases: a 10-year follow-up favors MR guidance.

Philippe Lucien Pereira, Panagiota Siemou, Hans-Jörg Rempp, Rüdiger Hoffmann, Ralf Thorsten Hoffmann, Joachim Kettenbach, Stephan Clasen, Thomas Helmberger

Abstract readMulticenter StudyComparative StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Philippe Lucien PereiraCenter for Radiology, Minimally-Invasive Therapies and Nuclear Medicine, SLK Kliniken GmbH Heilbronn, Heilbronn, Germany. philippe.pereira@slk-kliniken.de.ORCID http://orcid.org/0000-0002-9913-2120
Panagiota SiemouRadiology Department, Alexandra General Hospital, Athens, Greece.
Hans-Jörg RemppDepartment of Diagnostic and Interventional Radiology, Eberhard-Karls-University of Tübingen, Tübingen, Germany.
Rüdiger HoffmannDepartment of Diagnostic and Interventional Radiology, Eberhard-Karls-University of Tübingen, Tübingen, Germany.
Ralf Thorsten HoffmannInstitute and Policlinic for Diagnostic and Interventional Radiology, Carl-Gustav Carus University of Dresden, Dresden, Germany.
Joachim KettenbachInstitute for Diagnostic and Interventional Radiology and Nuclear Medicine, Wiener Neustadt, Austria.
Stephan ClasenDepartment of Diagnostic and Interventional Radiology, Eberhard-Karls-University of Tübingen, Tübingen, Germany.
Thomas HelmbergerClinic for Radiology, Neuroradiology and Nuclear Medicine Bogenhausen, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo compare the results of CT- vs MR-guided radiofrequency ablation (RFA) of liver metastases (LM) from colorectal cancer after 10 years of follow-up in an observational, retrospective, and multicentric study.

methodsA total of 238 patients with 496 LM were treated with RFA either with CT (CT group) or magnetic resonance (MR group) guidance. Every ablated LM was assessed and followed up with diagnostic MRI. Technical success, technique efficacy, predictive factors, recurrence rates, and overall survival were assessed.

resultsThe CT group comprised 143 patients and the MR group 77 patients. Eighteen patients underwent ablation with both modalities. Technical success per patient and per lesion was 88% and 93% for CT and 87% and 89.6% for MR, and technique efficacy was 97.1% and 98.6% for CT and 98.7% and 99.3% for MR respectively. Local recurrence following the first ablation (primary patency) occurred in 20.1% (CT) vs 4.6% (MR) (p < 0.001). Residual liver tumor, size of LM, and advanced N and M stage at initial diagnosis were independent predictors for overall survival in both groups. The median overall survival measured from first RFA treatment was 2.6 years. The 1-year, 5-year, and 10-year survival were 85.9%, 25.5%, and 19.1% respectively.

conclusionsThe MR group had significantly better local control compared to the CT group. There was no significant difference in patient survival between the two groups. CLINICAL RELEVANCE STATEMENT: MR-guided radiofrequency ablation of colorectal liver metastases is safe and effective, and offers better local control than CT-guided ablation. KEY POINTS: • Imaging modality for radiofrequency ablation guidance is an independent predictor of local recurrence in colorectal liver metastases. • MR-guided radiofrequency ablation achieved better local control of liver metastases from colorectal cancer than CT-guided. • The number and size of liver metastases are, among others, independent predictors of survival. Radiofrequency ablation with MR guidance improved clinical outcome but does not affect survival.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsRadiofrequency AblationTomography, X-Ray ComputedAdultAgedAged, 80 and overCatheter AblationFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesColorectal liver metastasesMagnetic resonance imagingMultidetector computed tomographyRadiofrequency ablation

Identifiers

PMID38041717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.